Amorfix, QED Bioscience To Jointly Develop Novel Monoclonal Antibodies
As per the agreement, QED is expected to generate monoclonal antibodies against several disease specific epitopes (DSE’s) on misfolded CD38 protein. The DSE’s were identified by Amorfix using
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.